Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets... Show more
a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BRF | 16.30 | 0.40 | +2.53% |
| VanEck Brazil Small-Cap ETF (BRF) | |||
| DEUS | 63.86 | 0.37 | +0.58% |
| Xtrackers Russell US Multifactor ETF (DEUS) | |||
| GOVI | 25.32 | 0.06 | +0.24% |
| Invesco Equal Weight 0-30 Year Treasury ETF (GOVI) | |||
| DRNL | 5.36 | N/A | N/A |
| Defiance 2X Daily Long Pure Drone and Aerial Automation ETF | |||
| JGRW | 27.45 | -0.06 | -0.22% |
| Jensen Quality Growth ETF (JGRW) | |||
A.I.dvisor indicates that over the last year, NEPH has been loosely correlated with SGHT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NEPH jumps, then SGHT could also see price increases.
| Ticker / NAME | Correlation To NEPH | 1D Price Change % | ||
|---|---|---|---|---|
| NEPH | 100% | N/A | ||
| SGHT - NEPH | 34% Loosely correlated | -3.53% | ||
| IMDX - NEPH | 31% Poorly correlated | -3.34% | ||
| GH - NEPH | 28% Poorly correlated | -2.02% | ||
| LUCY - NEPH | 27% Poorly correlated | +1.18% | ||
| AZTA - NEPH | 25% Poorly correlated | -1.18% | ||
More | ||||
| Ticker / NAME | Correlation To NEPH | 1D Price Change % |
|---|---|---|
| NEPH | 100% | N/A |
| Pharmaceuticals category (154 stocks) | 11% Poorly correlated | -0.74% |
| Pharmaceuticals: Other category (50 stocks) | 10% Poorly correlated | -0.52% |
NEPH saw its Momentum Indicator move below the 0 level on September 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 78 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 81%.
NEPH moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEPH crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for NEPH moved above the 200-day moving average on September 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEPH advanced for three days, in 162 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
NEPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 135 of 142 cases where NEPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.656) is normal, around the industry mean (5.011). P/E Ratio (25.188) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.318) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. NEPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.